Dihexa vs PE-22-28
Emerging vs Emerging
synergistic Complementary neuroplasticity pathways.
Molecular Data
Dihexa PE-22-28
Weight 504.7 Da 773.89 Da
Half-life 8-12 days Approximately 23 hours
Chain — 7 amino acids
Type Modified oligopeptide Linear heptapeptide
Key Benefits
Dihexa
01 Dramatic synaptogenesis promotion
02 10 million times more potent than BDNF
03 Cognitive enhancement and memory improvement
04 Neuroprotection and potential neuroregeneration
05 Applications for Alzheimer's, TBI, age-related cognitive decline
06 Oral bioavailability
PE-22-28
01 Rapid antidepressant effects within 4 days (preclinical)
02 Hippocampal neurogenesis and synaptogenesis
03 Enhanced serotonergic neurotransmission
04 Extended ~23 hour duration of action
05 300-500x greater potency than full-length Spadin
Dosing Protocols
Dihexa
8-10mg oral or 2-5mg injectable (0.5mg/kg based on research) / Once daily in the morning
Research protocol 0.5mg/kg daily Daily or 3x weekly
Standard injectable 2-5mg total 1x daily
PE-22-28
50-200mcg daily / Once daily
Antidepressant Effect 50-200mcg Once daily
Neurogenesis Support 100-200mcg Once daily
Side Effects
Dihexa
Headaches (most frequent side effect)
Anxiety or overstimulation
Sleep disruption when dosed late in day
Mental clarity increase
PE-22-28
No effects on TREK-2, TRAAK, TASK-1 channels observed
No cardiac dysfunction or seizures in preclinical studies
Contraindications
Not FDA approved - research compound only
Theoretical cancer risk via c-Met activation
Cancer history (avoid due to c-Met pathway)
Pregnancy or breastfeeding
No long-term human safety data
Pregnancy and breastfeeding
Concurrent MAOI use
Research Evidence
Dihexa PE-22-28
Status Emerging Emerging
References 3 studies 3 studies
Latest 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.